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Abstract
In order to identify genetic factors related to thyroid cancer susceptibility, we adopted a candidategene approach.We studied
tag- and putative functional SNPs in genes involved in thyroid cell differentiation and proliferation, and in genes found to be
differentially expressed in thyroid carcinoma. A total of 768 SNPs in 97 genes were genotyped in a Spanish series of 615 cases
and 525 controls,the formercomprising the largest collection of patientswiththis pathology from a single population studied
to date. SNPs in an LD block spanning the entire FOXE1 gene showed the strongest evidence of association with papillary
thyroid carcinoma susceptibility. This association was validated in a second stage of the study that included an independent
Italian series of 482 patients and 532 controls. The strongest association results were observed for rs1867277 (OR[per-
allele]=1.49; 95%CI=1.30–1.70; P=5.9610
29). Functional assays of rs1867277 (NM_004473.3:c.2283G.A) within the FOXE1
59 UTR suggested that this variant affects FOXE1 transcription. DNA-binding assays demonstrated that, exclusively, the
sequence containing the A allele recruited the USF1/USF2 transcription factors, while both alleles formed a complex in which
DREAM/CREB/aCREM participated. Transfection studies showed an allele-dependent transcriptional regulation of FOXE1.W e
propose a FOXE1 regulation model dependent on the rs1867277 genotype, indicating that this SNP is a causal variant in
thyroid cancer susceptibility. Our results constitute the first functional explanation for an association identified by a GWAS and
thereby elucidate a mechanism of thyroid cancer susceptibility. They also attest to the efficacy of candidate gene approaches
in the GWAS era.
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Introduction
Thyroid cancer is the most common endocrine malignancy, and
accounts for 1% of all neoplasias [1]. Among them, papillary
thyroid carcinoma (PTC, 80–85 % of cases), and follicular thyroid
carcinoma (FTC, 5–10 %) are the most frequent [2]. The etiology
of PTC, both sporadic (95 % of cases) and familial (about 5 %),
seems to be rather complex. Exposure to ionizing radiation and
deficiency in iodine intake have been suggested as environmental
risk factors related to PTC and FTC, respectively [3]. Different
PLoS Genetics | www.plosgenetics.org 1 September 2009 | Volume 5 | Issue 9 | e1000637genetic alterations involving the RET/PTC-RAS-BRAF signalling
pathway have been described as causal somatic changes in PTC
and FTC [4–9]. In addition, PTC has a strong genetic component,
since it shows one of the highest relative risks (FRR=8.60–10.30)
in first degree relatives of probands among cancers not displaying
Mendelian inheritance [10,11]. Several putative loci associated
with familial forms of PTC have been suggested by linkage analysis
[12–15], although no high penetrance gene has been convincingly
described, even within the putative loci, probably due to the
heterogeneity of the disease. Finally, microRNAs (miRs) have also
been suggested to be involved in the disease [16,17], although their
specific role remains unclear.
Therefore, it is expected that thyroid cancer is the result of
multiple low- to moderate-penetrance genes (LPGs) interacting
with each other and with the environment, thus modulating
individual susceptibility [10,18]. In this scenario, linkage analysis
does not have the power to identify these LPGs [19,20]. Thus,
GWAS or carefully designed candidate gene approaches may be
more appropriate strategies to define genetic risk factors.
We performed a candidate gene association study in thyroid
cancer, showing that FOXE1, formerly called TTF2 (Thyroid
Transcription Factor 2), exhibits the strongest association with
PTC susceptibility. FOXE1 itself is a good candidate LPG because
it is the centre of a regulatory network of transcription factors and
cofactors that initiate thyroid differentiation [21] and whose
function is essential for thyroid gland formation and migration, as
well as for the maintenance of the thyroid differentiated state in
adults [22].
Our study, which involves the largest collection of patients with
this pathology from a single population to be studied to date, also
identifies a causal variant within FOXE1 as well as the underlying
molecular mechanism involved. The variant rs1867277
(NM_004473.3:c.2283G.A) within the FOXE1 59 UTR affects
gene transcription through differential recruitment of USF1/
USF2 transcription factors only when the 2283A allele is present.
By contrast, a protein complex in which DRE- and CRE-binding
proteins participate, binds to both alleles.
Recently, a genome-wide association study (GWAS) identified
two SNPs located at 9q22.23 and 14q13.3 that are strongly
associated with an increased risk of PTC and FTC [23]. The
closest gene to the top marker at 9q22.33, rs965513 (OR=1.75;
P=1.7610
227)i sFOXE1.
Overall, it is noteworthy that, in this particular case, both
strategies identify the same gene, although the study of carefully
selected candidate genes remains a more direct, practical and
efficient approach to reveal functional variants within LPGs.
Methods
Subjects
Patients diagnosed with thyroid cancer were recruited from the
Spanish hospital network. A total number of 615 cases were
available for the study, representing, to our knowledge, the largest
thyroid cancer series from a single population. Our series included
the main thyroid follicular-cell derived carcinomas: 520 PTC,
represented by their main subtypes ‘classic PTC’ (cPTC; n=304)
and ‘follicular variant PTC’ (FVPTC; n=146), as well as 69
Follicular Thyroid Carcinomas (FTC). Medullary Thyroid
Carcinomas (MTC) were not included in the study, since we
previously performed a similar study of these cases [24]. Clinicians
fulfilled a detailed clinical questionnaire for all patients, which
included questions regarding both personal and clinical data, such
as tumour subtype and stage, surgery option, treatment details in
terms of
131I doses, and development of metastasis during the
follow-up. Diagnoses were assessed by pathologists from the
different institutions that participated in the study.
A series of 525 healthy controls, free of cancer and
representative of the Spanish population, were selected as the
reference group. These subjects came from the same geographical
regions as covered by the hospitals involved in the study. Informed
consent was obtained from all subjects included in the study.
Median age and sex ratio (female:male) were 46 years and 4.6,
respectively, in both cases and controls. Mean age and gender
distribution were similar in controls and cases (Mann-Whitney’s U
and Kruskal-Wallis associated Ps.0.05).
An additional 78 Spanish cases, obtained over the last year,
were genotyped for the significant SNP analyzed in most detail, in
order to increase the power of the test. These additional patients
were recruited from the same hospitals as the original Spanish
series. The distributions of thyroid cancer subtype, age and gender
were also similar to those of the first series (P.0.05).
A second stage of the study consisted of an independent Italian
series, used as a validation set, and was composed of 482 thyroid
cancer patients and 532 representative controls. Cases included
412 individuals with PTC and 44 with FTC. Their median age at
diagnosis and female:male sex ratio were 48.5 years and 4.9,
respectively. Italian controls were recruited from the same two
geographical regions as cases, and had a similar sex ratio and age
distribution as cases.
The design of the study is summarized in Figure S1.
DNA isolation and quantification
Blood (n=878) or saliva (n=262) samples were obtained from
Spanish patients and controls. Genomic DNA was extracted from
peripheral blood lymphocytes by automated DNA extraction
according to the manufacturer’s instructions (Magnapure, Roche)
and from saliva using the Oragene DNA Self-Collection Kit (DNA
Genotek, Ottawa, Canada). Genomic DNA was isolated from
Italian blood samples (n=1014) using standard methods [25].
DNA concentration was quantified in all samples prior to
genotyping by using Quant-iT PicoGreen dsDNA Reagent
(Invitrogen, Eugene, OR, USA).
Gene selection
We used a candidate gene approach in this study. Three
different criteria were used for selecting loci. First, we chose genes
Author Summary
Although follicular cell-derived thyroid cancer has an
important genetic component, efforts in identifying major
susceptibility genes have not been successful. Probably
this is due to the complex nature of this disease that
involves both genetic and environmental factors, as well as
the interaction between them, which could be ultimately
modulating the individual susceptibility. In this study,
focused on genes carefully selected by their biological
relation with the disease, and using more than 1,000 cases
and 1,000 representative controls from two independent
Caucasian populations, we demonstrate that FOXE1 is
associated with Papillary Thyroid Cancer susceptibility.
Functional assays prove that rs1867277 behaves as a
genetic causal variant that regulates FOXE1 expression
through a complex transcription factor network. This
approach constitutes a successful approximation to define
thyroid cancer risk genes related to individual susceptibil-
ity, and identifies FOXE1 as a key factor for its develop-
ment.
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and normal tissue [26], or as described in public databases, such as
CGAP-SAGE (http://cgap.nci.nih.gov/SAGE). Second, we pick-
ed genes involved in thyroid follicular cell biology and metabolism.
Finally, critical metabolic pathways such as the MAP kinase, JAK-
STAT and TGF-beta signaling pathways were represented by
selecting genes encoding proteins that play key roles in those
pathways (membrane receptors, signal transducers, transcription
factors, inhibitors, etc.). The latter criterion was applied after an
exhaustive review of the information contained in the pathway
databases KEGG Pathways (http://www.genome.ad.jp/kegg/
pathway.html), Biocarta (http://www.biocarta.com/genes/index.
asp), and Pathway Studio 4.0 (evaluation version). Candidate non-
coding MIRN genes were considered in the initial list using
miRBase (http://microrna.sanger.ac.uk/sequences/).
We ranked the loci based on the above criteria and finally
selected 97 genes for our association study (manuscript in
preparation).
SNP selection
The selected genes were represented by Single Nucleotide
Polymorphisms (SNPs) within the intragenic region and within the
regions spanning 10 kilobases upstream (to cover the hypothetical
entire promoter area) and 2 kilobases downstream of the gene. We
chose a total number of 768 SNPs, that can be divided into two
main categories: (i) 523 ‘tag SNPs’, used to infer Linkage
Disequilibrium (LD) blocks according the HapMap project
(http://www.hapmap.org/) [27]; and (ii) 245 potentially function-
al SNPs, as predicted by bioinformatic tools PupaSuite (http://
pupasuite.bioinfo.cipf.es/) [28] and F-SNP (http://compbio.cs.
queensu.ca/F-SNP/) [29]. Predictions of functionality included
SNPs that caused an aminoacid change in the protein (non-
synonymous SNPs), as well as those variants located within
putative transcription factor binding sites (TFBS) and exonic
splicing enhancers (ESE). SNP codes, locations, and frequencies
were obtained from the NCBI SNP database, build 126 (http://
www.ncbi.nlm.nih.gov/projects/SNP/).
The initial list of more than 52,000 SNPs fulfilling the above
criteria was filtered by applying the following additional criteria: (i)
a threshold minor allele frequency (MAF) in the HapMap-CEU
population of 0.10 for ‘tag SNPs’ and of 0.02 for putative
functional SNPs; and (ii) an ‘Illumina score’ not less than 0.6 (as
recommended by the manufacturer), to ensure a high genotyping
success rate. No variants within the MIRN genes considered were
described in the databases. Finally, we selected and genotyped 768
SNPs within 97 loci, thus fulfilling the platform requirements.
SNP genotyping
SNPs were genotyped using the Illumina GoldenGate Geno-
typing Assay (San Diego, CA, USA) system, on a Sentrix
Universal-96 Array Matrix multi-sample array format. Genotyp-
ing was carried out using 400 nanograms of DNA per reaction
following the manufacturer’s instructions (http://www.illumina.
com/). Genotyping specificity was assessed by including two DNA
duplicates (an intra-assay and an inter-assay duplicate) and a
negative control in each 96-well plate genotyped, yielding 100%
consistent replication results. In addition, cases and control
samples were always included in the same run.
Validation set genotyping was performed by means of the
KASPar SNP Genotyping System (Kbiosciences, Herts, UK).
Fifteen nanograms of DNA were used for the genotyping
reactions. The 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) was used for fluorescence
detection and allele assignment.
An additional variant, rs1867277, not included in the Illumina
assay, was selected for its predicted effect on the transcriptional
activity of FOXE1 to perform functional assays. This SNP was
analysed on a subset of 200 cases and controls by DHPLC on the
WAVE HT system (Transgenomic, Omaha, NE) using an
acetonitrile gradient; it was scrutinised for aberrant profiles with
the Navigator software (Transgenomic, Omaha, NE) to determine
the correlation between this potential functional SNP and the
other variants in FOXE1 genotyped by the Illumina platform.
Genotyping accuracy of both KASPar and DHPLC technolo-
gies was confirmed by direct sequencing of 5% of the samples
selected at random.
Cell cultures and plasmids
WRO cells derived from a human follicular thyroid carcinoma
were cultured as described [30]. The expression vectors used were
pcDNA3.1-DREAM [31], pSG5-aCREM [32], pGal4-CREB
[33], pN3 (USF1), pN4 (USF2) [34] and pUSF-1, expressing a
dominant negative form of USF1. The pGl3b-FOXE1 reporter
construct contains the 59 upstream regulatory region from 21934
to +539 bp relative to the transcription start site of human FOXE1
[35] and carries an A allele for the rs1867277 SNP. In this
plasmid, the A allele was replaced by the G allele (pGl3b-FOXE1-
283G) by means of site directed mutagenesis (QuikChange II XL
kit; Stratagene) following the manufacturer’s instructions using the
oligonucleotide 59-cagtcccggtc[g]cgaggccaccgc-39. The
c.2283A.G substitution and the absence of artefacts were
confirmed by direct sequencing. The vector pRL-CMV, contain-
ing a cDNA coding for Renilla, was used to monitor transfection
efficiency.
Electrophoretic mobility shift assays
Nuclear protein extracts from WRO cells were obtained
following standard procedures [36]. Specific proteins were
synthesized from the USF1/2 expression vectors pN3 and pN4
by in vitro transcription/translation using the TNT coupled
reticulocyte lysate system (Promega).
Seven mg of protein extracts or 3 ml of TNT pools were
incubated with 200 ng of the corresponding dsDNA probes
representing rs1867277-A: 59-gtcccggtcAcgaggccaccg-39 (referred
to as ‘‘Allele A’’); rs1867277-G: 59- gtcccggtcGcgaggccaccg-39
(‘‘Allele G’’); and the DRE element from the prodynorphin gene:
59- gaagccggagtcaaggaggcccctg-39 (‘‘DRE-pDyn’’), previously
labelled with c
32-ATP by T4 polynucleotide kinase. For
competition, a 100-fold excess of the same (‘‘related’’) or different
(‘‘unrelated’’: 59-ccataatgcaaaaatggaaagaattaaa-39) unlabeled oli-
gonucleotide was used as indicated in each experiment. Additional
dsDNA probes used were: the USF consensus sequence (USF-
cons) 59-cctgcccacgtgacccggcct-39; the CRE binding region of the
somatostatin gene (CRE-Cons) 59-cctcctagcctgacgtcagagagagagt-
39; and the CRE-like region of the FOXE1 gene (CRE-FOXE1) 59-
accagagtcgagtcccggtcacgaggcca-39. When required, specific anti-
bodies recognizing human DREAM, USF1, or USF2 (sc-9142, sc-
229 and sc-862, respectively, from Santa Cruz Biotechnologies)
were incubated together with protein extracts and dsDNAs.
EMSA conditions were similar to those described previously [24].
Transfection assays
Hela cells were transient transfected using the JetPei reagent
(PolyPlus Transfection) with different amounts of expression vector
(as indicated in each experiment); 3 mg of reporter construct and
60 ng of pRL-CMV were used. Forty-eight hours after transfec-
tion, cells were harvested, lysed, and analyzed for luciferase and
Renilla activities. The promoter activity in cells transfected with
FOXE1 and Thyroid Cancer Risk
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luciferase and Renilla, relative to the ratio obtained in cells
transfected with the corresponding empty expression vector. The
results shown are the average6SD of three independent
experiments, each performed in triplicate.
Statistical analysis
Departure from Hardy-Weinberg equilibrium (HWE) for all
SNPs was tested in controls using Fisher’s exact test. Associations
between each SNP and thyroid cancer risk were assessed using
Pearson’s x
2 test. Genotype frequencies in cases and controls were
compared and odds ratios (OR) per allele were estimated by
applying unconditional logistic regression, using homozygotes of
the most frequent allele in controls as the reference group.
Significant P values were adjusted for the putative confounding
factors age, gender, and population.
Haplotypes were inferred using PHASE 2.0, a computational
tool based on Bayesian methods. Case-control comparisons of
haplotype distributions were carried out by applying the inbuilt
permutation test, based on 10,000 permutations. Associations
between specific haplotypes and risk of thyroid cancer were
assessed using the Haplo.Stats package in R (http://www.R-
project.org).
For transfection assays, statistical significance was determined
by t-test analysis (two-tailed), and differences were considered
significant with P,0.05.
Statistical tests were performed using SPSS for Windows 17.0
software.
Results
Polymorphisms within the FOXE1 locus are significantly
associated with Papillary Thyroid Carcinoma in the Spanish
population
From the initial list of 768 variants, 33 SNPs (4 %) were
discarded due to a low fluorescence signal. Forty-five additional
polymorphisms (6 %) did not fulfill Hardy-Weinberg equilibrium
(P,0.05) in control samples and were excluded from the following
analyses. Overall, 690 SNPs (90 %) were studied. Among them,
top association results in the Spanish population were observed for
SNPs located within the FOXE1 locus (for the best tagSNP,
OR[per-allele]=1.47; 95% CI=1.23–1.75; P=2.4610
25),
strongly suggesting a putative LPG role for this gene, specifically
in the PTC subtype. Phase I association results are summarized in
Table 1. It is worthy to note that, when stratifying according to the
different PTC histological subtypes, a stronger association was
detected for FOXE1 SNPs exclusively for ‘classic PTC’ (Table S1).
Haplotype analysis identifies a highly significant risk
haplotype specifically associated with classic PTC cases
Five out of six significant SNPs in FOXE1 were located in a
single LD block (Figure 1), and were subsequently used for
haplotype analysis of the region spanning from chromosomal
coordinates 99,648,503 to 99,668,059 (Figure 1, Table 2). This
approach, used to reinforce results from individual SNP studies,
showed a significant difference in haplotype distribution between
all PTC cases and controls (PHASE associated P=0.0147). Again,
these differences were stronger when considering the classic PTC
subtype (PHASE associated P=0.0005, Table S2). Among the ten
haplotypes inferred in our population, three represented 95% of
individuals. The remaining seven haplotypes showed frequencies
lower than 1%, and were not considered for further analyses. A
detailed study of the three mentioned FOXE1 haplotypes (shown in
Table 2), allowed us to identify a risk haplotype significantly
overrepresented in classic PTC patients (OR=1.66; P=0.0005).
A detailed analysis of the PTC-risk conferring haplotype
identifies rs1867277 as a highly correlated putative
functional variant within the FOXE1 promoter
Since none of the six FOXE1-associated variants showed a
consistent putative functional role (according to the bioinformatics
tools used), a more detailed analysis of the sequence across this LD
region was performed. This allowed us to identify a functionally
interesting SNP (rs1867277, -283G.A), not initially included in
the Illumina assay. According to bioinformatics predictions, this
variant may influence the binding of transcription factors that
could regulate FOXE1 transcription. DHPLC results in a subset of
200 individuals allowed us to experimentally confirm a complete
LD between this functional variant (rs1867277) and the rs907577
tagSNP (included in the Illumina assay), and thus to impute
genotypes of the first variant (OR[per allele]=1.39;
P=2.1610
24). This correlation is represented in Figure 1, and
specific LD values are provided in Table S3.
Interestingly, the risk haplotype identified (Table 2, haplotype
#2), included the rs907577 G allele and the functional variant
rs1867277 A (located only 797 bases downstream), which has an
effect on FOXE1 transcription (see below).
Phase II association study validates FOXE1 rs1867277 in
Papillary Thyroid Cancer
An independent Italian population (phase II) validated the
phase I association results for the rs1867277 FOXE1 promoter
variant. This polymorphism was found to be significantly
Table 1. Significant polymorphisms in the FOXE1 locus when comparing Papillary Thyroid Cancer patients against controls in the
Spanish population (Phase I).
SNP name Coordinate Location
Function/
prediction
Alleles
(major/minor)
Genotyped samples
(controls/cases)
MAF in
controls
MAF in
cases OR
a (95% CI) P
rs7048394 99645254 Upstream tagSNP C/T 504/520 0.243 0.315 1.46 (1.19–1.78) 2.4610
24
rs894673 99652091 Upstream tagSNP T/A 504/520 0.400 0.482 1.39 (1.17–1.65) 2.2610
24
rs3758249 99653961 Upstream TFBS G/A 503/517 0.399 0.483 1.39 (1.17–1.66) 1.9610
24
rs907577 99654938 Upstream TFBS A/G 503/518 0.399 0.482 1.39 (1.17–1.65) 2.1610
24
rs3021526 99656842 Exon 1 S275S T/C 495/475 0.398 0.469 1.32 (1.11–1.58) 2.1610
23
rs10119760 99664423 Downstream tagSNP C/G 504/518 0.344 0.437 1.47 (1.23–1.75) 2.4610
25
aOR [per allele] obtained by comparing cases against controls and considering the minor allele as the risk allele.
MAF, Minor Allele Frequency; OR, Odds Ratio; CI, Confidence Interval; TFBS, Transcription Factor Binding Site.
doi:10.1371/journal.pgen.1000637.t001
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PLoS Genetics | www.plosgenetics.org 4 September 2009 | Volume 5 | Issue 9 | e1000637Figure 1. LD plot representation of the FOXE1 locus. The figure represents linkage disequilibrium based on the HapMap-CEU population data
(Data Release 24/phase II Nov08, on NCBI B36 assembly, dbSNP b126) along the FOXE1 locus. The region spans chromosome 9 from coordinates
99,645,254 to 99,668,082 for a total length of 22.82 kilobases. The FOXE1 gene is represented in yellow (exon) and grey (59 and 39 untranslated
regions). LD is measured by D’/LOD parameters (top panel) and the r-squared correlation value (bottom panel). D’ and r-squared values of 1 mean
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Italian controls (OR[per allele]=1.64; 95% CI=1.31–2.05;
adjusted P=1.3610
25). Phase I, II, and combined analyses for
both series are summarized in Table 3. Pool analysis for rs1867277
in 984 PTC cases vs. 1028 controls confirmed the involvement of
this FOXE1 variant in PTC development (OR[per allele]=1.49;
95% CI=1.30–1.70; adjusted P=5.9610
29).
The transcription factor DREAM binds within the FOXE1
promoter at the region containing the rs1867277 risk
variant
rs1867277 lies within a sequence with high similarity to the
DRE consensus core sequence described for the prodynorphin
promoter region [37] (Figure 2). In a first attempt to evaluate the
role of rs1867277 in the transcriptional regulation of FOXE1,
nuclear extracts from WRO cells were tested for their ability to
bind both A and G alleles in an EMSA assay. As shown in
Figure 3A, protein/DNA complexes were differentially formed
when using A and G-allele probes (lanes 2 and 5, respectively): a
lower complex was formed with both alleles, while an upper
complex was formed exclusively with the A allele. The complexes
were specific, as they were competed by a 100-fold excess of
unlabelled related oligonucleotide (lanes 3 and 6) but not by an
unrelated one (lanes 4 and 7).
In order to identify the transcription factors that bind to both
alleles, we first focused on DREAM (Downstream Regulatory
Element Antagonist Modulator) since rs1867277 contains a
putative DRE consensus sequence (Figure 2). When the prody-
norphin promoter containing the DRE consensus sequence (DRE-
pDYN) was used as a probe, a specific complex with the same
mobility as the A or G-allele lower band was detected (Figure 3A,
lane 8; related and unrelated competition, lanes 9 and 10).
Interestingly, this complex was partially competed by A and G-
allele oligonucleotides (lanes 11 and 12). Furthermore, a specific
DREAM antibody substantially reduced the intensity of the lower
band (lane 14). These data demonstrate the involvement of
endogenous DREAM in the lower shifted complex, although the
lack of total competition when oligonucleotides containing the A
or G allele were used, suggests that other proteins may be a part of
this complex. Intriguingly, a CRE-like sequence was identified
close to rs1867277 (Figure 2); CRE-binding factors can behave as
interacting partners of DREAM [38].
USF proteins bind specifically to the rs1867277 A allele
As the upper complex was exclusively formed when the A allele
was present, we decided to identify the transcription factor/s that
form part of that complex by interrogating databases (Gene
Regulation, http://www.gene-regulation.com). The Upstream
Stimulatory Factors (USF1 and USF2) were predicted to bind
exclusively to the rs1867277 A allele.
Thus, EMSAs with the A allele were performed with different
oligonucleotides as competitors, including a USF consensus
sequence and several oligonucleotides containing CRE sequences,
due to the relationship between DRE- and CRE (Figure 3B).
When the oligonucleotide containing the G allele was used, only
the lower complex was competed, demonstrating the specificity of
the upper complex for the A allele (lane 5). Similarly, CRE-like
FOXE1, the consensus CRE sequence, and consensus DRE-pDyn
competed exclusively with the lower band (lanes 6–8), suggesting
that the lower complex contains more than one transcription
factor. Interestingly, the upper band was totally competed when
the USF consensus sequence was used (lane 9). Furthermore, the in
vitro translated (TNT) USF1 or USF2 proteins formed a complex
with a similar mobility as the upper complex (lanes 11–12). When
specific antibodies against either transcription factor were added,
the upper complex formed over the A allele was supershifted when
using nuclear extracts (Figure 3C, lanes 6 and 14), and also when
using in vitro translated USF proteins (lanes 8 and 16). This
unequivocally demonstrates that USF1/USF2 form part of the
upper complex. On the other hand, the rs1867277 G allele shift
and supershift experiments using the same approach did not show
this upper DNA-protein complex (not shown).
Altogether, these results strongly indicate that only the
rs1867277 A allele is able to form a protein complex that includes
the transcription factors USF1 and USF2. In addition, both
rs1867277 A and G form a complex in which DREAM and
possibly other CRE-binding related transcription factors partici-
pate.
USF1 and USF2 regulate transcriptional activity of the
FOXE1 promoter
To validate the functional significance of the transcription factors
identified for FOXE1 gene expression, Hela cells were transiently
transfected with expression vectors harbouring the cDNAs of the
different transcription factors, together with the FOXE1 reporter
construct containing the rs1867277 A allele (pGl3b-FOXE1-283A).
While DREAM transfection did not generate significant variations
in FOXE1 promoter activity, USF1 and USF2 transfection
increased this activity (P,0.01 and P,0.05, respectively)
(Figure 4A). Since USF homo- and heterodimer formation has
been described [39], we cotransfected both expression vectors
simultaneously, and observed a large increase (8-fold, P,0.0001) of
FOXE1 promoter activity. This effect was specific, since it was
abolished when a dominant negative form of USF was cotrans-
fected. Moreover, cotransfection of the DREAM expression vector
together with USF1/USF2 clearly reduced the activation of the
FOXE1 reporter when compared to the USF1/USF2 condition
(P,0.0001), confirming the corepressor function of DREAM
[31,40]. All these data highlight the relevant regulatory role of
USF factors in the expression of FOXE1, as well as the inhibitory
effect of DREAM on USF-dependent FOXE1 activation. To verify
that the effect of the USF factors is mediated through the previously
mentioned putative USF binding site in the A allele, transient
transfection assays were performed using pGl3b-FOXE1-283G, the
reporter construct containing the G allele. No effect was found for
USF1 and USF2 when used independently, and simultaneous
cotransfection of USF1/2 resulted in a transcriptional activation
that wasclearlyless than that observed withthe A allele(P,0.0001).
In summary, the rs1867277 G allele partially impairs the
recruitment of USF1/2 factors to the FOXE1 promoter and alters
the expression status of the FOXE1 gene.
aCREM and CREB isoforms activate FOXE1 transcription
through a CRE site located close to rs1867277
Transcriptional activation of the FOXE1 gene is regulated by
hormonal factors, particularly by TSH via cAMP [41]. The
complete LD. The region is tagged by the SNPs shown in the figure, all of which were highly significant in the phase I association study. The
functional variant rs1867277 is shown in blue, and the tagSNP rs907577 is shown in red. Specific LD values between these two variants are shown in
the figure (four-point star).
doi:10.1371/journal.pgen.1000637.g001
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sequences within the promoters of genes regulated by cAMP. Given
the existence of a CRE-like site located near rs1867277 (Figure 2), we
evaluated the role of aCREM and CREB in FOXE1 regulation.
Overexpression of the two isoforms induced significant increases of
FOXE1 promoter activity, with aCREM being the most potent
activating factor (changes .50 fold) (Figure 4B). In order to evaluate
how this aCREM-dependent activation could be modified by the
transcription factors that bind within the FOXE1 promoter at the
region containing the rs1867277 risk variant, various amounts of the
USF1, USF2, CREB and DREAM expression vectors were
transfected alone or in combination with fixed amounts of aCREM
expression vector and FOXE1 reporter. USF1/USF2 and CREB did
not affect aCREM-induced FOXE1 reporter activity, while DREAM
overexpression led to an 80% repression (P,0.0001). Considering
these data, CRE-binding factors are acting as positive regulators of
FOXE1gene expression, while DREAM displaysa negative regulatory
effect on aCREM-dependent regulation. Moreover, USF factors do
not modulate the transcriptional activity of aCREM, which suggests
the existence of two independent regulatory mechanisms that include
DREAM and CRE-binding factors or USF proteins.
Discussion
In the present work, by means of a two-step candidate-gene
association study, we haveidentified FOXE1asa low penetrance gene
(LPG) associated with papillary thyroid cancer (PTC). Regression
analysis allowed us to pinpoint several SNPs within the FOXE1 locus
as highly significant risk-conferring variants for PTC. Haplotype
analysis, followed by an exhaustive search within the sequence of the
LD block containing the FOXE1 gene, enabled us to identify a
promoter SNP (rs1867277; c.2283 G.A) that we postulate to be a
causal variant due to its predicted effect on a transcription factor
binding site. The association results for this variant were validated in
an independent population. The combined OR [per allele] was 1.49
(95% CI=1.30–1.70; P=5.9 610
29). Functional assays revealed that
the c.2283A allele led to a differential recruitment of USF1 and
USF2 transcription factors.
Thyroid cancer is believed to be a complex disease, in which
common genetic variants located in low penetrance genes may
interact with each other and with the environment, determining
individual susceptibility. Our association results suggest that
FOXE1 is especially important for developing the classic PTC
subtype, which represents around half of the PTC cases. This
observation provides a basis for the heterogeneity described for
this neoplasia, which includes more than 15 histological subtypes.
Therefore, we propose that FOXE1 is acting as an LPG related to
thyroid cancer, which is in agreement with the increasing evidence
of forkhead box (Fox) proteins having a crucial role in the
development and progression of cancer, and their emerging role as
potential biomarkers [42].
The FoxE1 transcription factor belongs to the forkhead family
of transcription factors. These factors share a highly conserved
winged helix DNA binding domain that is able to interact with
nucleosomes and alter chromatin structure, creating a local
exposed domain necessary for the action of other transcription
factors. This property defined FOXE1 as a pioneer transcription
factor [43], whose action is essential for the development,
differentiation, and hormone responsiveness of the thyroid gland
[22]. Thus, the control of its expression must be exquisitely
regulated. However, few data are available concerning the
transcription factors involved in FOXE1 expression in the thyroid,
although the fact that TSH controls FOXE1 expression through
cAMP and Ca
2+ [41,44] suggests that CRE- and Ca
2+-binding
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PLoS Genetics | www.plosgenetics.org 7 September 2009 | Volume 5 | Issue 9 | e1000637factors may play a key role. In fact, sequence analysis of the
FOXE1 promoter, where rs1867277 (c.2283G.A) is located,
revealed the existence of a DRE site, similar to the one previously
found by D’Andrea et al. [45] and that shared a high similarity
with a previously defined consensus DRE site in the prodynorphin
gene [37]. Unexpectedly, functional assays showed that the Ca
2+-
dependent transcription factor DREAM bound equally well to
both rs1867277 alleles.
The most remarkable functional data obtained was the
formation of a DNA-protein complex exclusively between the A
allele and USF1/USF2 factors. These are ubiquitously expressed
proteins, which belong to the basic helix-loop-helix (HLH) leucine
zipper family of transcription factors. They share a highly
conserved C-terminal domain responsible for dimerization and
DNA binding, which recognizes the canonical E-box sequence
CACGTG [39,46]. The involvement of USF factors in FOXE1
regulation was confirmed by a transfection approach. These
factors, which mainly act as heterodimers, induced significant
increases in FOXE1 transcriptional activity when the rs1867277 A
allele was present. These data agree both with the role of USF
factors as positive transcriptional regulators of their target genes
[47] and with the predominant role of USF1/USF2 heterodimers
in comparison with homodimers [39].
Moreover, interactions between N-terminal domains of USF
dimers and cell-specific transcription factors have been described to
be involved in cooperative transcriptional regulation [48]. Interest-
ingly, we identified a potential CRE site located near the rs1867277
sequence, which could act as a target of CRE-related proteins
(CREB and aCREM). Transient transfection assays demonstrated
that CREB, and more strongly aCREM, activate the FOXE1
promoter, while DREAM reduces significantly aCREM depen-
dent-transcriptional induction. These data suggest a direct compe-
tition between CRE-bindingfactors andDREAMforbindingto the
FOXE1 promoter, which will ultimately control the transcriptional
status of the FOXE1 gene. In fact, it has been described that Ca2+
and cAMP concentrations modulate a regulatory network which
linksCRE-bindingproteinsandDREAM[38,49].Inthisway,these
transcription factors could regulate the expression of FOXE1 in
response to TSH in a physiological situation.
Given that both CRE proteins and USF factors are associated
with an increase in FOXE1 expression levels through closely
neighbouring sites, the question arises if these factors also cooperate
to regulate FOXE1 transcription. Our results showed no synergistic
effect of aCREM and USF1/2 proteins on FOXE1 transcription,
which is in agreement with other reports [50,51]. It therefore
remainstobeelucidated whichadditional proteins,ifany,areacting
together with USF proteins in modulating FOXE1 expression.
Finally, considering the specific binding of USF factors to the
disease risk-conferring rs1867277 A allele, an increased expression
of FOXE1 in thyroid follicular cell tumours in comparison to
normal thyrocytes is to be expected. Few data are available
regarding FOXE1 status in thyroid cancer, although Sequeira et al
demonstrated that an increased FOXE1 expression paralleled the
dedifferentiation process of thyroid carcinomas [52]. Therefore, it
is necessary to understand in which manner FOXE1, a thyroid
transcription factor involved in the maintenance of the differen-
tiated adult thyroid phenotype, could be involved in acquiring a
malignant status. One possible explanation relies on the results
obtained from FOXE1 knockout mouse models. During embryonic
development, thyroid cell precursors require FOXE1 transcription
initiallyto allowtheir own migrationfrom thethyroid bud, and later
Table 3. Combined association results for FOXE1 promoter variant rs1867277 (c.2283 G.A) in Papillary Thyroid Carcinoma
patients against controls.
Genotyped samples rs1867277 A frequency Unadjusted results Adjusted results
g
(n PTC/ n controls) PTC Controls
OR het
d
(95% CI)
OR hom
e
(95% CI)
OR per allele
(95% CI) P
f
OR per allele
(95% CI) P
f
Spain (518/503)
a 0.482 0.399 1.46 (1.10–1.94) 1.90 (1.34–2.71) 1.39 (1.17–1.65) 2.1610
24 1.38 (1.15–1.64) 3.9610
24
Spain (579
b/503) 0.484 0.399 1.50 (1.14–1.97) 1.95 (1.38–2.74) 1.41 (1.19–1.67) 8.5610
25 1.39 (1.17–1.65) 1.8610
24
Italy (405/525)
c 0.558 0.456 1.64 (1.18–2.30) 2.38 (1.62–3.50) 1.54 (1.27–1.87) 9.9610
26 1.64 (1.31–2.05) 1.3610
25
Spain+Italy (984/1028) 0.515 0.428 1.48 (1.20–1.83) 2.01 (1.56–2.59) 1.42 (1.25–1.61) 4.2610
28 1.49 (1.30–1.70) 5.9610
29
ars1867277 genotypes inferred from adjacent tagSNP rs907577, after proving a total Linkage Disequilibrium between both variants (see body text).
bAn additional 61 Spanish PTC genotyped for rs1867277 by means of KASPar technology.
cValidation series genotyped for rs1867277 by means of KASPar probes.
dOR heterozygous: GG vs. AG genotypes.
eOR homozygous: GG vs. AA genotypes.
fP values are derived from ORs [per allele].
gAdjusted for age, gender, and origin.
PTC, Papillary Thyroid Carcinoma; OR, Odds Ratio; CI, Confidence Interval.
doi:10.1371/journal.pgen.1000637.t003
Figure 2. Sequence analysis of rs1867277 in the FOXE1
promoter. (Top Panel) The A risk allele is shown in red and marked
with an arrow. Nucleotides in blue indicate mismatches with regard to
the DREAM consensus sequence, and gaps (indicated by dashes) are
introduced into the sequences of both alleles to optimize alignment
with the DREAM binding site. The DRE site derived from the human
prodynorphin (h-pDYN) promoter is underlined. (Bottom Panel)
Alignment of sequences close to the A and G alleles; consensus CRE-
and USF-transcription factor binding sites are underlined. Bases in blue
indicate differences with the consensus sequences.
doi:10.1371/journal.pgen.1000637.g002
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PLoS Genetics | www.plosgenetics.org 8 September 2009 | Volume 5 | Issue 9 | e1000637Figure 3. EMSAs show that different nuclear proteins bind to the FOXE1 rs1867277 region. (A) Nuclear extracts were prepared from WRO
cells for EMSA assays with
32P-labeled oligonucleotides corresponding to rs1867277 A, rs1867277 G, or the consensus DRE derived from the
prodynorphin promoter (DRE-pDYN). The probes were incubated without (lane 1) or with nuclear extracts (lanes 2 to 14). Competition was performed
with a 100-fold molar excess of unlabeled related (lanes 3, 6, 9), unrelated (lanes 4, 7, 10,) or alleles A and G (lanes 11 and 12) oligonucleotides, as well
as with an anti-DREAM antibody (lane 14). Protein/DNA complexes are indicated by arrows. (B) A
32P-labeled probe containing the oligonucleotide
corresponding to the rs1867277 A allele was incubated alone (lane 1); with WRO nuclear extracts (lanes 2-9); or with TNT translated proteins from
empty vector (lane 10), or from USF1 or USF2 expression vectors (lanes 11, 12). Competition was performed with a 100-fold molar excess of unlabeled
related (lane 3), unrelated (lane 4), allele G (lane 5), CRE-FOXE1 (lane 6), CRE consensus (lane 7), DRE-pDYN (lane 8), or USF consensus (lane 9)
oligonucleotides. (C) A
32P-labeled probe containing the oligonucleotide corresponding to the rs1867277 A allele was incubated alone (lanes 1, 9);
with WRO nuclear extracts (lanes 2–6 and 10–14); or with TNT-translated USF1 (lanes 7, 8) or USF2 protein (lanes 15, 16). Competition was performed
with a 100-fold molar excess of unlabeled USF consensus (lanes 3 and 11), unrelated (lanes 4 and 12), or allele G (lanes 5 and 13) oligonucleotides. In
addition, supershift assays were performed with specific anti-USF1 (lanes 6 and 8) or anti-USF2 (lanes 14 and 16) antibodies. Protein/DNA complexes
are indicated by arrows. The amount of proteins incubated with the probes was 7 mg of WRO nuclear extracts and 3 ml of TNT reaction for in vitro
translated proteins.
doi:10.1371/journal.pgen.1000637.g003
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PLoS Genetics | www.plosgenetics.org 9 September 2009 | Volume 5 | Issue 9 | e1000637Figure 4. Transcriptional activity of the FOXE1 promoter. (A) The FOXE1 promoter containing the A allele (pGl3b-FOXE1-A) or the G allele (pGl3b-
FOXE1-283G) was cotransfected into HeLa cells with 3 mg of the empty expression vector, or with 3 mg of the vector harbouring the cDNAs for DREAM, USF1,
USF2, or a dominant negative (DN) form of USF1. When USFs were cotransfected together, only 1.5 mgo fe a c he x p r e s s i o nv e c t o rw a su s e d .P r o m o t e ra c t i v i t y
is expressed as fold induction, relative to the activity observed in the presence of empty expression vector. (B) The FOXE1 promoter containing the A allele
was cotransfected into HeLa cells with empty expression vectors or the same vector harbouring the cDNAs for a-CREM, CREB, USF1, USF2, or DREAM in the
combinations shown in the figure. Numbers in the left hand panel represent mg of expression vector transfected; in the right hand panel, 3 mgo ft h e
indicated transcription factors were cotransfected. Promoter activity is expressed as fold induction, relative to the activity observed in the presence of empty
(left) or a-CREM (right) expression vectors. Luciferase activity was normalized to Renilla activity derived from the cotransfected pRL-Tk vector to adjust for
transfection efficiency. Results are mean6SD of four independent experiments. (*):P,0.05; (**):P=0.01–0.001; (***):P,0.001; ns, not significant.
doi:10.1371/journal.pgen.1000637.g004
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these data, we hypothesised that increased FOXE1 expression in
thyroid carcinomas could be related to a motile advantage of
malignant thyroid cells, which would be enhanced by the presence
of the rs1867277 A risk predisposing allele. While FOXE1-specific
studies are needed to further understanding the role of this gene in
thyroid tumour cell migration and invasion, several studies have
confirmed a tumoral role of forkhead family of transcriptional
factors. In this regard, genes encoding forkhead factors, among
others, have been recently identified as a molecular signature for
Epithelial to Mesenchymal transition in a human colon cancer [54]
and overexpression of FOX factors has been described in several
cancers [55–62]. This opens an interesting future for understanding
the role of FOXE1 in thyroid tumour cell migration and invasion.
Taken together, our association study, combined with a
functional assessment, allowed us to pinpoint a causal variant
within the FOXE1 promoter, and to propose a mechanism by
which this causal variant acts as a genetic risk factor specifically
related to PTC susceptibility. This finding reveals the importance
of considering a complex disease such as thyroid cancer as a
heterogeneous entity. It is crucial not to study complex diseases as
a collective, but to cluster cases according to homogeneous and
well-established clinical features. It seems obvious that just one
variant cannot explain the phenotype, and many other signals and
mechanisms may be also involved. However, our results are an
important step forward in understanding the disease, offering new
insights into the genetic mechanism involved in non-medullary
thyroid cancer development. It is also important to remember that
the complex nature of each locus could be operative through
additional variants or mechanisms.
In addition, our study validates the results of the first GWAS
performed in thyroid cancer [23], and addresses one of the major
limitations of GWAS: the enormous difficulty to provide a link between
a significant intergenic tagSNP and the precise variant that has a causal
role and provides a biological explanation [63]. The modest power to
identify causal variants using GWAS is in part because, in this
hypothesis-free approach, approximately 20% of common SNPs are
partially tagged, and rare variants are not tagged at all. Overall, our
study provides proof that, when reliable biological knowledge or
expression data from the tissues of interest are available, candidate gene
approaches can be straightforward to identify low penetrance genes
and to find putative causal variants within those genes.
Supporting Information
Figure S1 Layout of the two-step association study. The
diagram summarizes our two-step association approach, which
initially included a Spanish series (Phase I) of 615 cases and 525
controls. Seventy-eight additional Spanish cases were subsequently
included and analysed by KASPar platform. Phase II, composed
of 482 cases and 532 Italian controls, was used as a validation set.
Top association results were obtained for the functional variant
rs1867277 (shown in blue), within FOXE1 gene. P values (also
shown in Table 3) correspond to papillary thyroid cancer (PTC)
cases versus controls. Small boxes indicate the genotyping platform,
the mean age, and the female:male ratio (matched in cases and
controls) of each group.
Found at: doi:10.1371/journal.pgen.1000637.s001 (2.04 MB TIF)
Table S1 Association results for FOXE1 SNPs in the Spanish
population (Phase I) after stratification by subtype.
Found at: doi:10.1371/journal.pgen.1000637.s002 (0.04 MB
DOC)
Table S2 Group-specific associated P values obtained using the
PHASE program for the haplotype distribution between Spanish
cases and controls.
Found at: doi:10.1371/journal.pgen.1000637.s003 (0.03 MB
DOC)
Table S3 Pairwise Linkage Disequilibrium values, expressed as
D’ parameter, for the Illumina tested SNPs within the FOXE1 LD
block, the functional variant rs1867277, and the top associated
SNP rs965513 by Gudmundsson et al.
Found at: doi:10.1371/journal.pgen.1000637.s004 (0.05 MB
DOC)
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